Avicanna Inc - Asset Resilience Ratio
Avicanna Inc (AVCN) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Avicanna Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Avicanna Inc's Asset Resilience Ratio has changed over time. See Avicanna Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Avicanna Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Avicanna Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Avicanna Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Avicanna Inc Industry Peers by Asset Resilience Ratio
Compare Avicanna Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Wockhardt Limited
NSE:WOCKPHARMA |
Drug Manufacturers - Specialty & Generic | 5.19% |
|
CHRISTINA LAKE CANNABIS
F:CLB |
Drug Manufacturers - Specialty & Generic | 0.19% |
|
Moberg Pharma AB (publ)
ST:MOB |
Drug Manufacturers - Specialty & Generic | 4.15% |
|
Canopy Growth Corp
NASDAQ:CGC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Zhejiang Nhu Co Ltd
SHE:002001 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS
IS:ECILC |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750 |
Drug Manufacturers - Specialty & Generic | 3.67% |
|
Beijing Science Sun Pharmaceutical Co Ltd
SHE:300485 |
Drug Manufacturers - Specialty & Generic | 41.01% |
Annual Asset Resilience Ratio for Avicanna Inc (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Avicanna Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$22.30 Million ≈ $16.13 Million |
-- |
| 2020-12-31 | 4.15% | CA$1.25 Million ≈ $904.23K |
CA$30.16 Million ≈ $21.81 Million |
-- |
| 2019-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$45.16 Million ≈ $32.67 Million |
-- |
| 2018-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$28.18 Million ≈ $20.39 Million |
-- |
| 2017-12-31 | 0.47% | CA$10.00K ≈ $7.23K |
CA$2.12 Million ≈ $1.53 Million |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more